Holy Stone Healthcare Co., Ltd. (TPEX:4194)

Market Cap	1.03B -38.9%
Revenue (ttm)	47.51M -78.6%
Net Income	-139.59M
EPS	-0.96
Shares Out	145.97M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	86,704
Average Volume	116,480
Open	6.90
Previous Close	7.00
Day's Range	6.69 - 7.03
52-Week Range	5.32 - 12.65
Beta	0.73
RSI	37.39
Earnings Date	Mar 26, 2026

About Holy Stone Healthcare

Holy Stone Healthcare Co., Ltd. develops and sells hyaluronic acid-related therapeutic products in Taiwan. The company offers RenehaVis, a product designed to relive pain and stiffness of the knee joint; SportVis, a treatment to relive the pain and optimize the recovery of tendon and ligament injuries; TRUD, a treatment that allows mucosal tissue to heal naturally and reduces the symptoms of ulcerative colitis; and GAF, a treatment for anal mucosal lesions. It is also developing IBD98-M, which is in Phase II a clinical trials for the treatment ...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2001
• Country: Taiwan
• Stock Exchange: Taipei Exchange
• Ticker Symbol: 4194

Financial Performance

In 2024, Holy Stone Healthcare's revenue was 118.77 million, a decrease of -49.86% compared to the previous year's 236.89 million. Losses were -183.49 million, -36.59% less than in 2023.